Viatris stock price forecast remains steady despite macroeconomic uncertainties, with portfolio diversification mitigating revenue volatility. To be a shareholder in Viatris today, you need to believe in the company’s ability to create sustainable growth by streamlining operations, diversifying beyond mature generic products, and delivering on new launches in areas like chronic disease and ophthalmology. The appointment of Andrew Enrietti to a newly centralized transformation role signals Viatris’ ongoing commitment to improving operational efficiency, but has limited immediate impact on the most important short-term catalyst: approval and successful commercialization of higher-margin products. The core risk, persistent margin pressure from price erosion and regulatory changes, remains unchanged as the central challenge to watch. We recently published an article titled Why These 15 Large-Cap Stocks Are Plunging So Far In 2025 . In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against the other large-cap stocks. Technical analysis of Viatris stock price forecast shows a 50-day moving average crossing above the 200-day, potentially signaling a mid-term bullish phase.